联系客服

002581 深市 未名医药


首页 公告 未名医药:2019年主要经营业绩

未名医药:2019年主要经营业绩

公告日期:2020-04-30

未名医药:2019年主要经营业绩 PDF查看PDF原文
山东未名生物医药股份有限公司

      2019 年主要经营业绩

          2020 年 04 月


                        目录


第一节 重要提示...... 2
第二节 公司基本情况...... 4
第三节 重要事项...... 6
第四节 财务报表...... 10

                      第一节 重要提示

    公司董事、监事、高级管理人员保证主要经营业绩内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,且与经审计年报报告不存在重大差异,并承担个别和连带的法律责任。


                    第二节 公司基本情况

一、主要会计数据和财务指标
公司是否需追溯调整或重述以前年度会计数据
√ 是 □ 否
追溯调整或重述原因
会计差错更正;同一控制下企业合并

                                                                    上年同期          本报告期比上年同
                                          本报告期                                          期增减

                                                              调整前        调整后          调整后

营业收入(元)                              610,638,764.31  664,593,783.42  673,760,750.96          -9.37%

归属于上市公司股东的净利润(元)              43,778,120.64  -95,789,054.12 -102,895,146.00          142.55%

归属于上市公司股东的扣除非经常性损

益的净利润(元)                              39,421,984.83  -88,574,215.51  -95,680,307.39          141.20%

经营活动产生的现金流量净额(元)              32,177,563.51  74,456,075.43 -350,496,622.30          109.18%

基本每股收益(元/股)                              0.0664        -0.1452        -0.1560          142.56%

稀释每股收益(元/股)                              0.0664        -0.1452        -0.1560          142.56%

加权平均净资产收益率                                1.57%        -3.33%        -3.67%            5.24%

                                                                    上年度末          本报告期末比上年
                                        本报告期末                                        度末增减

                                                              调整前        调整后          调整后

总资产(元)                              3,472,315,962.96 4,298,453,211.03 4,316,747,151.29          -19.56%

归属于上市公司股东的净资产(元)          2,375,469,716.01 2,762,104,211.80 2,775,081,794.24          -14.40%

会计政策变更的原因及会计差错更正的情况

    公司 2019 年自查发现,控股股东北京北大未名生物工程集团有限公司(以下简称“未名集团”)自 2017 年 12 月至 2019
年 6 月,以预付工程款、预付研发款及预付备用金等方式,占用公司全资子公司未名生物医药有限公司及其控股子公司天津
未名生物医药有限公司自有资金余额共计人民币 5.07 亿元。截至 2019 年 12 月 31 日,非经营性占用资金余额人民币 5.07
亿元,利息人民币 0.54 亿元。需追溯调整往期数据,将预付工程款、预付研发款及预付备用金等对应的会计科目调整为对未名集团的其他应收款项。

    2019 年 12 月 31 日,未名集团以其拥有的,四个生物新药及吉林未名天人中药材科技发展有限公司(以下简称“吉林
未名“)100%的 股权抵偿未名集团占用上市公司的资金及利息。由于吉林未名与本公司同属未名集团控制,属同一控制下企业合并,需追溯调整往期数据。

    以上调整对 2018 年度财务报表的影响:

(一)对合并资产负债表的影响

          项目                      更正前                    更正金额                    更正后


货币资金                            1,545,695,278.42                  80,519.18          1,545,775,797.60

其他应收款                            11,165,481.90            427,218,510.32            438,383,992.22

存货                                  42,129,162.94              13,068,196.64              55,197,359.58

其他流动资产                          262,180,538.03            -100,000,000.00            162,180,538.03

固定资产                              460,523,529.67                110,598.36            460,634,128.03

在建工程                              350,657,146.27            -31,000,000.00            319,657,146.27

递延所得税资产                        23,786,817.38              2,796,291.87              26,583,109.25

其他非流动资产                        363,647,308.76            -293,980,176.11              69,667,132.65

应付职工薪酬                          24,582,048.13                113,410.22              24,695,458.35

应交税费                              10,834,673.10              1,930,522.03              12,765,195.13

其他应付款                            32,860,818.96              3,272,425.57              36,133,244.53

资本公积                            1,354,712,322.59              15,029,427.09          1,369,741,749.68

未分配利润                          1,036,925,481.27              -2,051,844.65          1,034,873,636.62

 (二)对合并利润表的影响

          项目                      更正前                    更正金额                    更正后

营业收入                              664,593,783.42              9,166,967.54            673,760,750.96

营业税金及附加                          8,297,346.80                    100.00              8,297,446.80

管理费用                              120,135,021.23                371,124.60            120,506,145.83

财务费用                              48,067,503.09                    -193.12              48,067,309.97

资产减值损失                          166,923,739.32              17,090,568.01            184,014,307.33

所得税费用                              9,381,371.76              -1,188,540.07              8,192,831.69

归母净利润                            -95,789,054.12              -7,106,091.88            -102,895,146.00

(三)对合并现金流量表的影响

          项目                      更正前                    更正金额                    更正后

收到其他与经营活动有关的

现金                                  364,488,704.96                372,253.12            364,860,958.08

支付给职工以及为职工支付

的现金                                140,387,231.26                235,354.27            140,622,585.53

支付的各项税费                        81,344,550.17                  3,460.00              81,348,010.17

支付其他与经营活动有关的

现金                            
[点击查看PDF原文]